Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

Elena Shagisultanova

TitleAsst Professor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Elias AD, Spoelstra NS, Staley AW, Sams S, Crump LS, Vidal GA, Borges VF, Kabos P, Diamond JR, Shagisultanova E, Afghahi A, Mayordomo J, McSpadden T, Crawford G, D'Alessandro A, Zolman KL, van Bokhoven A, Zhuang Y, Gallagher RI, Wulfkuhle JD, Petricoin Iii EF, Gao D, Richer JK. Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancer. NPJ Breast Cancer. 2023 May 20; 9(1):41. PMID: 37210417.
      View in: PubMed
    2. Shagisultanova E, Gao D, Callihan E, Parris HJ, Risendal B, Hines LM, Slattery ML, Baumgartner K, Schedin P, John EM, Borges VF. Overall survival is the lowest among young women with postpartum breast cancer. Eur J Cancer. 2022 06; 168:119-127. PMID: 35525161.
      View in: PubMed
    3. Rasti AR, Guimaraes-Young A, Datko F, Borges VF, Aisner DL, Shagisultanova E. PIK3CA Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. JCO Precis Oncol. 2022 03; 6:e2100370. PMID: 35357905.
      View in: PubMed
    4. Shagisultanova E, Crump LS, Borakove M, Hall JK, Rasti AR, Harrison BA, Kabos P, Lyons TR, Borges VF. Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2. Mol Cancer Ther. 2022 01; 21(1):48-57. PMID: 34728571.
      View in: PubMed
    5. Kagihara JA, Shagisultanova E, Afghahi A, Diamond JR. Moving Towards Targeted Therapies for Triple-Negative Breast Cancer. Curr Breast Cancer Rep. 2021 Sep; 13(3):216-226. PMID: 34457184.
      View in: PubMed
    6. Stoen E, Kagihara J, Shagisultanova E, Fisher CM, Nicklawsky A, Kabos P, Borges VF, Diamond JR. Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval. Breast Cancer Res Treat. 2021 Jun; 187(3):883-891. PMID: 33625615.
      View in: PubMed
    7. West AH, Knollman H, Dugan J, Hedeker D, Handorf EA, Nielsen SM, Bealin LC, Goldblatt LG, Willems H, Daly MB, Afghahi A, Olopade OI, Hulick PJ, Shagisultanova E, Huo D, Obeid E, Churpek JE. Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study. Cancer Med. 2019 09; 8(12):5609-5618. PMID: 31407530.
      View in: PubMed
    8. Korobeynikov V, Borakove M, Feng Y, Wuest WM, Koval AB, Nikonova AS, Serebriiskii I, Chernoff J, Borges VF, Golemis EA, Shagisultanova E. Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer. Breast Cancer Res Treat. 2019 Sep; 177(2):369-382. PMID: 31254157.
      View in: PubMed
    9. Weiss J, Afghahi A, Shagisultanova E, Diamond JR. Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2- Breast Cancer. Oncology (Williston Park). 2018 Oct 15; 32(10):513-5. PMID: 30334242.
      View in: PubMed
    10. Schedin TB, Borges VF, Shagisultanova E. Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition. Int J Breast Cancer. 2018; 2018:7835095. PMID: 30018827.
      View in: PubMed
    11. Shagisultanova E, Mayordomo J, Elias AD. Triple-negative breast cancer in the elderly. Breast J. 2017 11; 23(6):627-629. PMID: 29112794.
      View in: PubMed
    12. Lev A, Deihimi S, Shagisultanova E, Xiu J, Lulla AR, Dicker DT, El-Deiry WS. Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer. Cancer Biol Ther. 2017 Sep 02; 18(9):694-704. PMID: 28886275.
      View in: PubMed
    13. Deihimi S, Lev A, Slifker M, Shagisultanova E, Xu Q, Jung K, Vijayvergia N, Ross EA, Xiu J, Swensen J, Gatalica Z, Andrake M, Dunbrack RL, El-Deiry WS. BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations. Oncotarget. 2017 Jun 20; 8(25):39945-39962. PMID: 28591715.
      View in: PubMed
    14. Jasem J, Fisher CM, Amini A, Shagisultanova E, Rabinovitch R, Borges VF, Elias A, Kabos P. The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided? J Natl Compr Canc Netw. 2017 04; 15(4):494-503. PMID: 28404760.
      View in: PubMed
    15. Overholser L, Shagisultanova E, Rabinovitch RA, Kounalakis N, Diamond J, Finlayson CA, Fisher CM, Kabos P, Elias AD, Borges VF, Mayordomo J. Breast Cancer Following Radiation for Hodgkin Lymphoma: Clinical Scenarios and Risk-Reducing Strategies. Oncology (Williston Park). 2016 12 15; 30(12):1063-70. PMID: 27987198.
      View in: PubMed
    16. Beck TN, Georgopoulos R, Shagisultanova EI, Sarcu D, Handorf EA, Dubyk C, Lango MN, Ridge JA, Astsaturov I, Serebriiskii IG, Burtness BA, Mehra R, Golemis EA. EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer. Mol Cancer Ther. 2016 10; 15(10):2486-2497. PMID: 27507850.
      View in: PubMed
    17. Shagisultanova E, Gaponova AV, Gabbasov R, Nicolas E, Golemis EA. Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases. Gene. 2015 Aug 01; 567(1):1-11. PMID: 25967390.
      View in: PubMed
    18. Shagisultanova E, Dunbrack RL, Golemis EA. Issues in interpreting the in vivo activity of Aurora-A. Expert Opin Ther Targets. 2015 Feb; 19(2):187-200. PMID: 25384454.
      View in: PubMed
    19. Shagisultanova EI, Piao Z, Li HR, Malkhosyan SR. Topoisomerase II gene mutations in tumors and tumor cell lines with microsatellite instability. Cancer Lett. 2004 Dec 28; 216(2):221-6. PMID: 15533598.
      View in: PubMed
    20. Li HR, Shagisultanova EI, Yamashita K, Piao Z, Perucho M, Malkhosyan SR. Hypersensitivity of tumor cell lines with microsatellite instability to DNA double strand break producing chemotherapeutic agent bleomycin. Cancer Res. 2004 Jul 15; 64(14):4760-7. PMID: 15256444.
      View in: PubMed
    21. Shagisultanova EI, Novikova IA, Sidorenko YS, Marchenko GN, Strongin AY, Malkhosyan SR. The matrix metalloproteinase-21 gene 572C/T polymorphism and the risk of breast cancer. Anticancer Res. 2004 Jan-Feb; 24(1):199-201. PMID: 15015597.
      View in: PubMed
    22. Mustafina OE, Shagisultanova EI, Tuktarova IA, Khusnutdinova EK. [Polymorphism of the apolipoprotein E gene and the risk of myocardial infarction]. Mol Biol (Mosk). 2002 Nov-Dec; 36(6):978-84. PMID: 12500534.
      View in: PubMed
    23. Mustafina OE, Shagisultanova EI, Tuktarova IA, Khusnutdinova EK. [Connection of HindIII-polymorphism of the lipoprotein lipase gene with risk of developing myocardial infarct]. Mol Biol (Mosk). 2001 May-Jun; 35(3):401-3. PMID: 11443920.
      View in: PubMed
    24. Mustafina OE, Shagisultanova EI, Nasibullin TR, Tuktarova IA, Bikmeeva AM, Poliudova ON, Khusnutdinova EK. [Endothelial nitric oxide synthase gene minisatellite polymorphism: study in populations of the Volga-Ural region and analysis of associations with myocardial infarct and essential hypertension]. Genetika. 2001 May; 37(5):668-74. PMID: 11436560.
      View in: PubMed
    Shagisultanova's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (150) concept(s)
    _
    Co-Authors Expand Description
    See all (23) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2023 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)